SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, presented data from a correlation study for its QuickVue iFOB (immunochemical Fecal Occult Blood) test for colorectal cancer (CRC) screening. The results demonstrated a high correlation between Quidel’s POC immunochemistry test and a quantitative laboratory test for fecal occult blood. The study, entitled “A New Method for Quantification of FOB Levels,” was introduced at the Colorectal Congress in St. Gallen, Switzerland on December 4th.
